[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华传染病杂志, 2019, 37(1):1-9.
[2] Hayashi PH, Rockey D, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology, 2017, 66(4): 1275-1285
[3] Girish C, Sanjay S. Role of immune dysfunction in drug induced liver injury. World J Hepatol, 2021,13(11):1677-1687.
[4] Zhang IW, Curto A, López-Vicario C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on -chronic liver failure. J Hepatol, 2022, 76(1): 93-106.
[5] Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci, 2021, 22(6):2954
[6] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int, 2016, 36(2):158-165.
[7] Habib S, Shaikh OS . Drug-induced acute liver failure. Clinics in Liver Disease, 2017, 21(1):151-162.
[8] Chayanupatkul M, Schiano TD . Acute liver failure secondary to drug-induced liver injury. Clinics in Liver Disease, 2020, 24(1):75-87.
[9] Reuben A, Koch DG, Lee WM, Acute liver failure study group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology, 2010, 52(6):2065-2076.
[10] Watkins PB. How to diagnose and exclude drug-induced liver injury. Dig Dis, 2015, 33(4):472-476.
[11] Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: A website on drug-induced liver injury. Hepatology, 2013, 57.
[12] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology, 2015, 148(7):1340-52.e1347.
[13] Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int, 2015, 35(7):1801-1808
[14] Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2021, 00:1-21.
[15] Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within two years of onset of drug-induced liver injury. Hepatology, 2017, 66(4): 1275-1285.
[16] Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int, 2018, 38(7):1322-1329.
[17] Jeong R, Lee YS, Sohn C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury . Scand J Gastroenterol, 2015, 50(4):439-446.
[18] Rathi C, Pipaliya N, Patel R, et al. Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol, 2017, 16(3): 442-450.
[19] Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology, 2014,147(1):109-118.
[20] Bonkovsky HL, Barnhart HX, Foureau DM, et al. Cytokine profiles in acute liver injury-results from the US drug-induced liver Injury network (DILIN) and the acute liver failure study group. Plos One, 2018, 13(10):e0206389.
[21] Lo Re V, Haynes K, Forde KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model.Clin Gastroenterol Hepatol, 2015, 13(13):2360-2368.
[22] Roth SE, Avigan MI, Bourdet D, et al. Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther, 2020,107(2): 333-346.
[23] Llewellyn HP, Vaidya VS, Wang Z, et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans . Toxicological Sciences, 2021,181(1):23-34.
[24] Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int, 2017, 37(5): 757-764.
[25] Arai M, Yokosuka O, Kanda T, et al. Serum osteopontin levels in patients with acute liver dysfunction. Scand. J. Gastroenterol, 2006, 41(1), 102-110.
[26] Church RJ, Kullak-Ublick GA, Aubrecht, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology, 2019, 69, 760-773.
[27] Bakshi S, Kaur M, Saini N, et al. Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers. Hum Exp Toxicol, 2021, 40(9):1474-1484. |
